Cleared Traditional

CREATINE KINASE (CK) REAGENT SET (K930660) - FDA 510(k) Clearance

Class II Chemistry device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K930660 · Pointe Scientific, Inc., · Chemistry device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Mar 1993
Decision
48d
Days
Class 2
Risk

K930660 is an FDA 510(k) clearance for the CREATINE KINASE (CK) REAGENT SET. Classified as Nad Reduction/nadh Oxidation, Cpk Or Isoenzymes (product code CGS), Class II - Special Controls.

Submitted by Pointe Scientific, Inc., (Lincoln Park, US). The FDA issued a Cleared decision on March 29, 1993 after a review of 48 days - a notably fast clearance cycle.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.1215 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Pointe Scientific, Inc., devices

Submission Details

510(k) Number K930660 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received February 09, 1993
Decision Date March 29, 1993
Days to Decision 48 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary Statement
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
40d faster than avg
Panel avg: 88d · This submission: 48d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code CGS Nad Reduction/nadh Oxidation, Cpk Or Isoenzymes
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.1215
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Chemistry devices follow this clearance model.

Regulatory Peers - CGS Nad Reduction/nadh Oxidation, Cpk Or Isoenzymes

All 122
Devices cleared under the same product code (CGS) and FDA review panel - the closest regulatory comparables to K930660.
Pointe Scientific Creatinine Kinase (CK) Reagent Set
K191296 · Medtest DX · Aug 2020
SEKURE Creatine Kinase Assay
K182702 · Sekisui Diagnostics P.E.I., Inc. · Apr 2019
CK
K983070 · Abbott Laboratories · Feb 1999
CREATINE KINASE (CK)
K981218 · Abbott Laboratories · May 1998
IL TEST CK-MB
K952646 · Instrumentation Laboratory CO · Aug 1995
CREATINE KINASE TEST
K931889 · Em Diagnostic Systems, Inc. · Jul 1993